Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Racial disparities in patient outcomes following catheter-directed thrombectomy for acute pulmonary embolism.

Heart & lung : the journal of critical care·2026
Same author

Cardiovascular Outcomes After Percutaneous Coronary Intervention in Patients With Serious Mental Illness.

International journal of psychiatry in medicine·2026
Same author

Frailty as a predictor of adverse in-hospital outcomes in older patients with Takotsubo cardiomyopathy.

Journal of geriatric cardiology : JGC·2026
Same author

SGLT2 Inhibitors and Progression of Chronic Kidney Disease in Patients With Elevated Lipoprotein(a): A RealWorld Cohort Study.

Journal of cardiovascular pharmacology·2026
Same author

Impact of comorbid mental disorders on in‑hospital mortality and complications after ST‑segment elevation myocardial infarction.

Future cardiology·2026
Same author

Unexpected Intraoperative Diagnosis of Acute Type A Aortic Dissection in an Octogenarian: Tailored Repair.

JACC. Case reports·2026

Related Experiment Video

Updated: Jun 18, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Comparative cardiovascular toxicity of immune checkpoint inhibitors: A real-world cohort study.

Abdul Rasheed Bahar1, Yasemin Bahar1, Mohamed Elhussain1

  • 1Wayne State University, Department of Medicine, Detroit, MI, USA.

The American Journal of the Medical Sciences
|June 16, 2026
PubMed
Summary

Programmed cell death-1 (PD-1) inhibitors increase myocarditis risk compared to programmed cell death ligand-1 (PD-L1) inhibitors. Cardiovascular outcomes were similar, but PD-1 inhibitors showed higher cardiac inflammation risks.

Keywords:
Cardio-oncologyComparative toxicityImmune checkpoint inhibitorsMyocarditis

Related Experiment Videos

Last Updated: Jun 18, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Area of Science:

  • Cardio-oncology
  • Immunotherapy
  • Pharmacovigilance

Background:

  • Immune checkpoint inhibitors (ICIs) enhance cancer treatment but can cause severe cardiovascular toxicity, such as myocarditis.
  • Existing data suggest potential cardiovascular risk disparities between PD-1 and PD-L1 inhibitors, necessitating real-world validation.

Purpose of the Study:

  • To compare cardiovascular outcomes between patients receiving PD-1 inhibitors and those receiving PD-L1 inhibitors.
  • To assess the real-world incidence of myocarditis and other cardiovascular events associated with these distinct ICI classes.

Main Methods:

  • A retrospective cohort study utilized the TriNetX global research network.
  • Propensity score matching (1:1) balanced baseline characteristics for PD-1 and PD-L1 inhibitor cohorts.
  • Incident myocarditis was the primary outcome, with secondary analyses of pericarditis, heart failure, and arrhythmias at 1 and 2 years.

Main Results:

  • PD-1 inhibitors were linked to a significantly higher risk of myocarditis at both 1 year (RR 1.49) and 2 years (RR 1.49).
  • Pericarditis incidence was also elevated with PD-1 inhibitors at 1 year (RR 1.28).
  • Rates of heart failure, arrhythmias, and cardiomyopathy phenotypes did not differ significantly between the two groups.

Conclusions:

  • PD-1 inhibitors are associated with increased immune-mediated cardiac inflammation compared to PD-L1 inhibitors.
  • Non-inflammatory cardiovascular outcomes were comparable across both ICI types.
  • Findings support enhanced cardiovascular monitoring for patients starting PD-1 therapy and suggest refined cardio-oncology risk stratification.